The FDA has asked Scynexis to hold new clinical studies of an intravenous formulation of its antifungal treatment, SCY-078, until the agency can review available pre-clinical and clinical data.
Source: Drug Industry Daily
The FDA has asked Scynexis to hold new clinical studies of an intravenous formulation of its antifungal treatment, SCY-078, until the agency can review available pre-clinical and clinical data.
Source: Drug Industry Daily